MA55064A - Composés utilisés comme inhibiteurs de kinase - Google Patents

Composés utilisés comme inhibiteurs de kinase

Info

Publication number: MA55064A
Authority: MA; Morocco
Prior art keywords: kinase inhibitors; compounds used; compounds; kinase; inhibitors
Prior art date: 2015-12-16

Application number

MA055064A

Other languages

English (en)

Inventor

Nicolas Guisot

Original Assignee

Loxo Oncology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-16

Filing date

2016-12-16

Publication date

2021-09-29

2015-12-16 Priority claimed from GBGB1522245.8A external-priority patent/GB201522245D0/en

2016-08-15 Priority claimed from GBGB1613945.3A external-priority patent/GB201613945D0/en

2016-12-16 Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc

2021-09-29 Publication of MA55064A publication Critical patent/MA55064A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

MA055064A 2015-12-16 2016-12-16 Composés utilisés comme inhibiteurs de kinase MA55064A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1522245.8A GB201522245D0 (en)	2015-12-16	2015-12-16	Compounds useful as kinase inhibitors
GBGB1613945.3A GB201613945D0 (en)	2016-08-15	2016-08-15	Compounds useful as kinase inhibitors

Publications (1)

Publication Number	Publication Date
MA55064A true MA55064A (fr)	2021-09-29

Family

ID=57590725

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA055064A MA55064A (fr)	2015-12-16	2016-12-16	Composés utilisés comme inhibiteurs de kinase
MA49809A MA49809A1 (fr)	2015-12-16	2016-12-16	Composés utilisés comme inhibiteurs de kinase

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA49809A MA49809A1 (fr)	2015-12-16	2016-12-16	Composés utilisés comme inhibiteurs de kinase

Country Status (37)

Country	Link
US (8)	US10695323B2 (fr)
EP (2)	EP3390395B1 (fr)
JP (3)	JP6731483B2 (fr)
KR (2)	KR20210018530A (fr)
CN (9)	CN114621146A (fr)
AU (4)	AU2016373530B2 (fr)
CA (1)	CA3008488C (fr)
CL (1)	CL2018001591A1 (fr)
CO (1)	CO2018006164A2 (fr)
CR (1)	CR20180367A (fr)
CY (2)	CY1123561T1 (fr)
DK (1)	DK3390395T3 (fr)
EA (1)	EA035132B1 (fr)
ES (2)	ES2828431T3 (fr)
FI (1)	FIC20240004I1 (fr)
FR (1)	FR24C1009I2 (fr)
HR (1)	HRP20201835T1 (fr)
HU (2)	HUE051921T2 (fr)
IL (4)	IL285976B2 (fr)
LT (2)	LT3390395T (fr)
MA (2)	MA55064A (fr)
MD (1)	MD3390395T2 (fr)
MX (2)	MX394193B (fr)
MY (2)	MY202026A (fr)
NL (1)	NL301262I2 (fr)
NO (1)	NO2024008I1 (fr)
NZ (1)	NZ743553A (fr)
PE (3)	PE20181449A1 (fr)
PH (1)	PH12018501268A1 (fr)
PT (1)	PT3390395T (fr)
RS (1)	RS60982B9 (fr)
SG (2)	SG11201805044WA (fr)
SI (1)	SI3390395T1 (fr)
TN (1)	TN2018000213A1 (fr)
UA (2)	UA122258C2 (fr)
WO (1)	WO2017103611A1 (fr)
ZA (4)	ZA201804137B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201410430D0 (en)	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
WO2017046604A1 (fr)	2015-09-16	2017-03-23	Redx Pharma Plc	Dérivés de pyrazolopyrimidine comme inhibiteurs de btk pour le traitement du cancer
HUE051921T2 (hu)	2015-12-16	2021-03-29	Loxo Oncology Inc	Kináz inhibitorként alkalmas vegyületek
GB201801226D0 (en)	2018-01-25	2018-03-14	Redx Pharma Plc	Modulators of Rho-associated protein kinase
JP7476167B2 (ja) *	2018-04-06	2024-04-30	アルトスラブス，インコーポレーテッド	Ａｔｆ６阻害剤およびその使用
CN112119063B (zh) *	2018-05-18	2023-10-17	富士胶片株式会社	3-二氟甲基吡唑化合物的制造方法及3-二氟甲基吡唑-4-羧酸化合物的制造方法以及吡唑烷化合物
US12109193B2 (en) *	2018-07-31	2024-10-08	Loxo Oncology Inc.	Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
WO2021028645A1 (fr)	2019-08-09	2021-02-18	Kalvista Pharmaceuticals Limited	Inhibiteurs de la kallicréine plasmatique
WO2021053234A1 (fr) *	2019-09-19	2021-03-25	Johann Wolfgang Goethe-Universität Frankfurt am Main	Composés et compositions pour le traitement d'une maladie rénale
CN110724135B (zh) *	2019-11-18	2023-04-28	上海医药工业研究院有限公司	一种艾拉普林中间体及其制备方法
MX2022006631A (es) *	2019-12-06	2022-09-07	Loxo Oncology Inc	Dosificacion de un inhibidor de la tirosina cinasa de bruton.
JP7649311B2 (ja)	2020-01-02	2025-03-19	ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド	Ｂｔｋ阻害薬
JP2023518006A (ja) *	2020-03-12	2023-04-27	フォチョン・バイオサイエンシーズ・リミテッド	キナーゼ阻害剤としての化合物
TWI809489B (zh)	2020-09-10	2023-07-21	美商絡速藥業公司	用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體
CN112386597B (zh) *	2020-10-15	2022-03-15	天津济坤医药科技有限公司	泽布替尼在制备治疗肺纤维化疾病药物中的应用
WO2022140246A1 (fr)	2020-12-21	2022-06-30	Hangzhou Jijing Pharmaceutical Technology Limited	Procédés et composés destinés à l'autophagie ciblée
CN116348453B (zh) *	2021-04-25	2025-07-04	烨辉医药科技(上海)有限公司	杂芳族甲酰胺化合物及其用途
US20240207229A1 (en)	2021-05-14	2024-06-27	Loxo Oncology, Inc.	Cocrystalline forms of a bruton's tyrosine kinase inhibitor
CA3223769A1 (fr) *	2021-07-01	2023-01-05	Xinglu ZHOU	Tyrosine kinase de bruton et agent de degradation mutant, composition et utilisation associees
CN115611810B (zh) *	2021-07-16	2025-03-04	深圳市塔吉瑞生物医药有限公司	取代的吡唑类化合物及包含该化合物的组合物及其用途
AU2022409472A1 (en)	2021-12-14	2024-06-27	Crossfire Oncology Holding B.V.	Macrocyclic btk inhibitors
WO2023143355A1 (fr) *	2022-01-28	2023-08-03	Hansoh Bio Llc	Dérivé d'amide d'azacycle, ses procédés de préparation et ses utilisations médicinales
US20250179027A1 (en) *	2022-03-03	2025-06-05	Shenzhen Targetrx, Inc.	Cycloalkyl or heterocyclyl substituted heteroaryl compound, and composition and use thereof
US20250188094A1 (en) *	2022-03-18	2025-06-12	Insilico Medicine Ip Limited	Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof
CN115894376B (zh) *	2022-12-15	2025-05-16	南京雷正医药科技有限公司	一种芳香族酰胺类化合物、药物组合物及其用途
WO2024176164A1 (fr)	2023-02-22	2024-08-29	Assia Chemical Industries Ltd.	Forme à l'état solide de pirtobrutinib
WO2024246287A1 (fr)	2023-06-02	2024-12-05	Crossfire Oncology Holding B.V.	Utilisation médicale d'un inhibiteur de btk réversible macrocyclique
WO2024245578A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur de btk irréversible et d'un inhibiteur de btk réversible macrocyclique
WO2024245577A1 (fr)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Combinaisons thérapeutiques d'un inhibiteur irréversible de btk et d'un inhibiteur réversible de btk
WO2024256574A1 (fr)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Procédé de préparation d'inhibiteurs de btk macrocycliques
WO2024256568A1 (fr)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Formes salines et formes cristallines d'un inhibiteur de btk macrocyclique
KR20250046558A (ko)	2023-09-27	2025-04-03	임창섭	5g 사물인터넷 기반 하드월렛 간의 디지털자산 안심이체 시스템
WO2025124496A1 (fr) *	2023-12-13	2025-06-19	正大天晴药业集团股份有限公司	Composé contenant un cycle pyrazole et un groupe hétéroaryle bicyclique, composition pharmaceutique et utilisation associées
WO2025137329A1 (fr) *	2023-12-22	2025-06-26	Neupharma, Inc	Entités chimiques particulières, compositions et procédés
CN119059973A (zh) *	2024-08-12	2024-12-03	武汉九州钰民医药科技有限公司	一种吡托布鲁替尼的合成工艺
CN119059974B (zh) *	2024-08-12	2025-10-28	武汉九州钰民医药科技有限公司	一种吡托布鲁替尼的制备方法
CN120504661B (zh) *	2025-07-14	2025-11-07	复旦大学	Alkbh8小分子抑制剂及其制备方法和用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1390219A (zh)	1999-09-17	2003-01-08	艾博特股份有限两合公司	作为治疗剂的吡唑并嘧啶类
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US6291504B1 (en) *	1999-10-20	2001-09-18	Dupont Pharmaceuticals Company	Acylsemicarbazides and their uses
US20030225098A1 (en)	2002-03-21	2003-12-04	Hirst Gavin C.	Kinase inhibitors
ES2585902T3 (es)	2006-09-22	2016-10-10	Pharmacyclics Llc	Inhibidores de tirosina cinasa de Bruton
MX2009003650A (es) *	2006-10-06	2009-04-22	Abbott Lab	Nuevos imidazotiazoles e imidazoxazoles.
WO2008054827A2 (fr)	2006-11-03	2008-05-08	Pharmacyclics, Inc.	Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation
BRPI0810086B1 (pt)	2007-03-28	2021-11-09	Pharmacyclics Llc	Composto inibidor de tirosina quinase de bruton, uso do referido composto e composição farmacêutica
DK2361248T3 (en)	2008-06-27	2019-01-14	Celgene Car Llc	Heteroberl compounds and uses thereof
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102159214A (zh)	2008-07-16	2011-08-17	药品循环公司	用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
BRPI0916356B1 (pt)	2008-07-24	2022-08-23	Nerviano Medical Sciences S.R.L	3,4-diaril pirazois como inibidores da proteína quinase
US8426428B2 (en)	2008-12-05	2013-04-23	Principia Biopharma, Inc.	EGFR kinase knockdown via electrophilically enhanced inhibitors
US7718662B1 (en)	2009-10-12	2010-05-18	Pharmacyclics, Inc.	Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
NZ702485A (en)	2010-06-03	2016-04-29	Pharmacyclics Llc	The use of inhibitors of bruton’s tyrosine kinase (btk)
EP3173407A1 (fr)	2010-06-30	2017-05-31	Ironwood Pharmaceuticals, Inc.	Stimulateurs de sgc
PL2710005T3 (pl)	2011-05-17	2017-07-31	Principia Biopharma Inc.	Inhibitory kinazy tyrozynowej
DK2710007T3 (da)	2011-05-17	2020-01-27	Principia Biopharma Inc	Kinasehæmmere
KR20140048968A (ko)	2011-07-13	2014-04-24	파마시클릭스, 인코포레이티드	브루톤형 티로신 키나제의 억제제
EP2548877A1 (fr)	2011-07-19	2013-01-23	MSD Oss B.V.	Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
MX368112B (es)	2012-06-18	2019-09-18	Principia Biopharma Inc	Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias.
WO2014022569A1 (fr)	2012-08-03	2014-02-06	Principia Biopharma Inc.	Traitement de la sécheresse oculaire
EP2882741B1 (fr) *	2012-08-10	2018-10-24	Boehringer Ingelheim International GmbH	Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
GB201214750D0 (en) *	2012-08-17	2012-10-03	Respivert Ltd	Compounds
CA2888960C (fr) *	2012-11-02	2017-08-15	Pfizer Inc.	Inhibiteurs de la tyrosine kinase de bruton
CN103848810A (zh) *	2012-11-30	2014-06-11	北京赛林泰医药技术有限公司	鲁顿酪氨酸激酶抑制剂
US8957080B2 (en)	2013-04-09	2015-02-17	Principia Biopharma Inc.	Tyrosine kinase inhibitors
GB201309085D0 (en)	2013-05-20	2013-07-03	Redx Pharma Ltd	Compounds
RS60934B1 (sr) *	2013-09-30	2020-11-30	Guangzhou Innocare Pharma Tech Co Ltd	Supstituisani nikotinimidni inhibitori btk i njihova priprema i upotreba u lečenju karcinoma, inflamatorne i autoimune bolesti
WO2015075051A1 (fr) *	2013-11-19	2015-05-28	Universitaet Des Saarlandes	Inhibiteurs allostériques de protéines kinases c atypiques
WO2015095099A1 (fr)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Inhibiteurs de btk
KR20160117614A (ko)	2014-02-21	2016-10-10	프린시피아 바이오파마, 인코퍼레이티드	Btk 억제제의 염 및 고체 형태
GB201404987D0 (en) *	2014-03-20	2014-05-07	Redx Pharma Ltd	Compounds
CN105085474B (zh) *	2014-05-07	2018-05-18	北京赛林泰医药技术有限公司	鲁顿酪氨酸激酶抑制剂
GB201410430D0 (en)	2014-06-11	2014-07-23	Redx Pharma Ltd	Compounds
UA122221C2 (uk)	2015-01-28	2020-10-12	Байєр Фарма Акцієнгезелльшафт	4Н-ПІРОЛО[3,2-c]ПІРИДИН-4-ОНОВІ ПОХІДНІ
GB2548542A (en) *	2015-06-16	2017-09-27	Redx Pharma Plc	Compounds
WO2017046604A1 (fr)	2015-09-16	2017-03-23	Redx Pharma Plc	Dérivés de pyrazolopyrimidine comme inhibiteurs de btk pour le traitement du cancer
JOP20160198B1 (ar)	2015-09-16	2022-03-14	Janssen Pharmaceuticals Inc	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar)	2015-09-16	2020-08-27	Katholieke Univ Leuven Ku Leuven Research & Development	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PL3390390T3 (pl)	2015-12-16	2022-01-24	Boehringer Ingelheim International Gmbh	Pochodne bipirazolilu przydatne w leczeniu chorób autoimmunologicznych
JP6728382B2 (ja)	2015-12-16	2020-07-22	エコラブユーエスエイインク	膜濾過浄化のためのペルオキシギ酸組成物
US10669261B2 (en)	2015-12-16	2020-06-02	Bristl-Myers Squibb Company	Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
KR20180095871A (ko)	2015-12-16	2018-08-28	프리오스타 피티와이 엘티디	덴드리머 및 그의 배합물
HUE051921T2 (hu)	2015-12-16	2021-03-29	Loxo Oncology Inc	Kináz inhibitorként alkalmas vegyületek

2016
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
- 2016-12-16 MX MX2021003478A patent/MX394193B/es unknown
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 RS RS20201291A patent/RS60982B9/sr unknown
- 2016-12-16 CA CA3008488A patent/CA3008488C/fr active Active
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko not_active Withdrawn
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 CN CN202210312064.XA patent/CN114605327B/zh active Active
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 CN CN202111022488.4A patent/CN113603645B/zh active Active
- 2016-12-16 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/fr active Active
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 CN CN202210311995.8A patent/CN114634447B/zh active Active
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 CN CN202210312050.8A patent/CN114591242B/zh active Active
- 2016-12-16 MX MX2018007267A patent/MX380907B/es unknown
- 2016-12-16 EP EP20194724.9A patent/EP3782994B1/fr active Active
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/fr not_active Ceased
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active Active
- 2016-12-16 CN CN202111022492.0A patent/CN113636978B/zh active Active
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 CN CN202210310724.0A patent/CN114716381B/zh active Active
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 ES ES20194724T patent/ES3041897T3/es active Active
- 2016-12-16 MY MYPI2022003989A patent/MY202026A/en unknown
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 MY MYPI2022003990A patent/MY200590A/en unknown
- 2016-12-16 CN CN202210311970.8A patent/CN114573510B/zh active Active
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
2023
- 2023-07-31 US US18/362,249 patent/US12220401B2/en active Active
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-02-29 NO NO2024008C patent/NO2024008I1/no unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-04 CY CY2024003C patent/CY2024003I1/el unknown
- 2024-03-04 FR FR24C1009C patent/FR24C1009I2/fr active Active
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
- 2024-03-06 LT LTPA2024506C patent/LTPA2024506I1/lt unknown
- 2024-11-21 US US18/955,844 patent/US20250090500A1/en active Pending

Also Published As

Publication number	Publication date
ZA202107472B (en)	2023-03-29
US20200276162A1 (en)	2020-09-03
CR20180367A (es)	2018-11-12
IL281067A (en)	2021-04-29
PE20181449A1 (es)	2018-09-12
CN114573510B (zh)	2025-02-25
CN113636978B (zh)	2024-10-29
SI3390395T1 (sl)	2020-11-30
UA127863C2 (uk)	2024-01-31
US12220401B2 (en)	2025-02-11
SG11201805044WA (en)	2018-07-30
US20250090500A1 (en)	2025-03-20
CN113603645A (zh)	2021-11-05
ZA202107471B (en)	2023-03-29
EP3782994A1 (fr)	2021-02-24
WO2017103611A1 (fr)	2017-06-22
CY2024003I2 (el)	2024-09-20
ES3041897T3 (en)	2025-11-17
JP7419437B2 (ja)	2024-01-22
MY202026A (en)	2024-03-29
PH12018501268A1 (en)	2019-02-18
US20220062239A1 (en)	2022-03-03
US20230372298A1 (en)	2023-11-23
EA035132B1 (ru)	2020-04-30
IL276283B (en)	2021-03-25
FR24C1009I2 (fr)	2025-02-07
CY2024003I1 (el)	2024-09-20
SG10202012498TA (en)	2021-01-28
EP3782994B1 (fr)	2025-07-16
IL259923B (en)	2020-08-31
PE20220507A1 (es)	2022-04-07
CL2018001591A1 (es)	2018-09-28
US10342780B2 (en)	2019-07-09
EA201891268A1 (ru)	2018-11-30
IL259923A (en)	2018-07-31
CN108473481A (zh)	2018-08-31
US11471441B2 (en)	2022-10-18
EP3390395A1 (fr)	2018-10-24
CN114605327A (zh)	2022-06-10
DK3390395T3 (da)	2020-09-28
MX2021003478A (es)	2022-07-25
US10918622B2 (en)	2021-02-16
AU2021225161A1 (en)	2021-09-30
IL281067B (en)	2022-04-01
CA3008488A1 (fr)	2017-06-22
MX2018007267A (es)	2018-11-09
HK1263254A1 (en)	2020-02-21
US20190135762A1 (en)	2019-05-09
CN114591242A (zh)	2022-06-07
CN113603645B (zh)	2024-10-29
US20190000806A1 (en)	2019-01-03
ES2828431T3 (es)	2021-05-26
CN114573510A (zh)	2022-06-03
IL285976B1 (en)	2023-06-01
EP3390395B1 (fr)	2020-09-09
HUE051921T2 (hu)	2021-03-29
CN113636978A (zh)	2021-11-12
KR102215792B1 (ko)	2021-02-16
CA3008488C (fr)	2023-10-10
IL276283A (en)	2020-09-30
PT3390395T (pt)	2020-11-03
US10695323B2 (en)	2020-06-30
NO2024008I1 (no)	2024-02-29
MD3390395T2 (ro)	2021-02-28
ZA201804137B (en)	2022-08-31
PE20220502A1 (es)	2022-04-07
AU2021225162A1 (en)	2021-09-30
ZA202100544B (en)	2023-06-28
CN114621146A (zh)	2022-06-14
HRP20201835T1 (hr)	2021-01-08
AU2021225161B2 (en)	2023-08-03
UA122258C2 (uk)	2020-10-12
US20210093611A1 (en)	2021-04-01
JP2022120013A (ja)	2022-08-17
AU2021201811B2 (en)	2022-01-27
CN114591242B (zh)	2025-01-07
KR20180115261A (ko)	2018-10-22
RS60982B9 (sr)	2025-07-31
MX380907B (es)	2025-03-12
FIC20240004I1 (fi)	2024-03-01
NZ743553A (en)	2022-08-26
RS60982B1 (sr)	2020-11-30
JP6731483B2 (ja)	2020-07-29
CN114716381A (zh)	2022-07-08
CO2018006164A2 (es)	2018-09-20
AU2021201811A1 (en)	2021-04-22
KR20210018530A (ko)	2021-02-17
BR112018012341A2 (pt)	2018-12-04
MX394193B (es)	2025-03-21
LTPA2024506I1 (fr)	2024-03-25
MA49809A1 (fr)	2021-08-31
LT3390395T (lt)	2020-11-25
US11826351B2 (en)	2023-11-28
US10464905B2 (en)	2019-11-05
FR24C1009I1 (fr)	2024-05-24
IL285976B2 (en)	2023-10-01
NL301262I2 (nl)	2024-04-24
HUS2400003I1 (hu)	2024-03-28
MY200590A (en)	2024-01-04
CN108473481B (zh)	2022-04-19
JP7086140B2 (ja)	2022-06-17
CN114716381B (zh)	2025-03-11
CY1123561T1 (el)	2022-03-24
CN114605327B (zh)	2025-03-11
JP2018538307A (ja)	2018-12-27
TN2018000213A1 (en)	2019-10-04
US20180362512A1 (en)	2018-12-20
CN114634447B (zh)	2024-11-15
AU2021225162B2 (en)	2023-08-03
CN114634447A (zh)	2022-06-17
IL285976A (en)	2021-10-31
JP2020172535A (ja)	2020-10-22
AU2016373530A1 (en)	2018-07-05
AU2016373530B2 (en)	2021-01-21

Publication	Publication Date	Title
FR24C1009I2 (fr)	2025-02-07	Composés utilisés comme inhibiteurs de kinase
MA52119A (fr)	2018-08-29	Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr)	2021-04-28	Composés hétérocycliques utilisés comme immunomodulateurs
MA45669A (fr)	2019-05-22	Composés hétérocycliques utilisés comme immunomodulateurs
MA44860A (fr)	2019-03-13	Composés hétérocycliques utilisés comme immunomodulateurs
MA45116A (fr)	2021-06-02	Composés hétérocycliques comme immunomodulateurs
EP3720430A4 (fr)	2021-05-05	Composés benzocarbonyle
EP3691623A4 (fr)	2021-05-26	Composés de benzosulfonyle
MA51229A (fr)	2021-03-24	Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr
MA42923A (fr)	2021-04-28	Composés bicycliques comme inhibiteurs mixtes de atx/ca
EP3322409A4 (fr)	2019-07-24	Composés aza substitués comme inhibiteurs de l'irak-4
DK3303348T3 (da)	2019-11-11	Naphthyridinforbindelser som JAK-kinaseinhibitorer
MA41677A (fr)	2021-06-02	Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
EP3337787A4 (fr)	2019-05-08	Composés pyrazolo hétérocycliques condensés comme inhibiteurs d'erk
EP3397629A4 (fr)	2019-06-05	Composés inhibiteurs de métallo-enzymes
EP3319966A4 (fr)	2019-01-09	Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
MA41803A (fr)	2018-01-30	Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
DK3717488T3 (da)	2021-12-13	Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
EP3464336A4 (fr)	2020-01-15	Composés
EP3728289A4 (fr)	2021-10-13	Composés optimisés
EP3638237A4 (fr)	2021-01-13	Composés aminothiazoles utilisés comme inhibiteurs de protéine kinase
EP3310352A4 (fr)	2019-03-13	Composés cristallins
EP3717483A4 (fr)	2021-07-14	Composés de pyrazolopyridinone
EP3713941A4 (fr)	2021-04-14	Composés de pyrazolopyridinone
EP3481806C0 (fr)	2023-06-07	Composés de 4-anilino-quinoléine substitués comme agents anticancereux